-
1.发明申请公开(公告)号：US20050245745A1
公开(公告)日：2005-11-03
申请号：US10834459
申请日：2004-04-29
申请人： James Link , Marina Pliushchev , Jeffrey Rohde , Dariusz Wodka
发明人： James Link , Marina Pliushchev , Jeffrey Rohde , Dariusz Wodka
IPC分类号： C07D205/04 , C07D211/06 , C07D211/46 , C07D213/74 , C07D295/15
CPC分类号： C07D295/15 , C07D205/04 , C07D211/46 , C07D213/74
摘要： The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征以及其它疾病和病症的用途 由过度的糖皮质激素作用介导。
-
公开(公告)号：US20050245534A1
公开(公告)日：2005-11-03
申请号：US10965591
申请日：2004-10-14
申请人： James Link , Marina Pliushchev , Jeffrey Rohde , Dariusz Wodka , Jyoti Patel , Qi Shuai
发明人： James Link , Marina Pliushchev , Jeffrey Rohde , Dariusz Wodka , Jyoti Patel , Qi Shuai
IPC分类号： C07C237/04 , C07C237/24 , C07D207/02 , C07D209/08 , C07D213/06 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04 , A61K31/495 , A61K31/445 , A61K31/496 , C07D211/06 , C07D45/02
CPC分类号： C07D213/06 , C07C237/04 , C07C237/24 , C07C2601/02 , C07C2603/74 , C07D207/02 , C07D209/08 , C07D213/24 , C07D213/72 , C07D213/74 , C07D213/85 , C07D223/16 , C07D253/06 , C07D257/04 , C07D277/64 , C07D295/15 , C07D295/185 , C07D471/08 , C07D491/04
摘要： The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
公开(公告)号：US20050277647A1
公开(公告)日：2005-12-15
申请号：US11119022
申请日：2005-04-29
申请人： James Link , Yixian Chen , Hwan-Soo Jae , Jyoti Patel , Marina Pliushchev , Jeffrey Rohde , Qi Shuai , Bryan Sorensen , Martin Winn , Dariusz Wodka , Hong Yong
发明人： James Link , Yixian Chen , Hwan-Soo Jae , Jyoti Patel , Marina Pliushchev , Jeffrey Rohde , Qi Shuai , Bryan Sorensen , Martin Winn , Dariusz Wodka , Hong Yong
IPC分类号： A61K31/495 , C07D241/04
CPC分类号： C07D213/75 , C07D205/04 , C07D207/12 , C07D209/44 , C07D211/42 , C07D231/12 , C07D239/42 , C07D277/82 , C07D295/14 , C07D307/68 , C07D403/12 , C07D413/12 , C07D487/18 , C07D491/056
摘要： The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.
-
4.发明申请Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application 审中-公开11-β-羟基类固醇脱氢酶1型酶的抑制剂及其治疗应用公开(公告)号：US20050245532A1
公开(公告)日：2005-11-03
申请号：US10835132
申请日：2004-04-29
申请人： Ethan Hoff , James Link , Marina Pliushchev , Jeffrey Rohde , Martin Winn
发明人： Ethan Hoff , James Link , Marina Pliushchev , Jeffrey Rohde , Martin Winn
IPC分类号： A61K31/445 , A61K31/495 , A61K31/496
CPC分类号： A61K31/445 , A61K31/495 , A61K31/496
摘要： The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.
摘要翻译： 本发明涉及11-β-羟基类固醇脱氢酶1型酶抑制剂的用途。 本发明还涉及11-β-羟基类固醇脱氢酶1型酶抑制剂用于治疗或预防性治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其它疾病的用途，以及 过度糖皮质激素作用介导的病症。
-
5.发明申请Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application 审中-公开11-β-羟基类固醇脱氢酶1型酶的抑制剂及其治疗应用公开(公告)号：US20050245533A1
公开(公告)日：2005-11-03
申请号：US10965239
申请日：2004-10-14
申请人： Ethan Hoff , James Link , Marina Pliushchev , Jeffrey Rohde , Martin Winn
发明人： Ethan Hoff , James Link , Marina Pliushchev , Jeffrey Rohde , Martin Winn
IPC分类号： A61K31/445 , A61K31/495 , A61K31/496
CPC分类号： A61K31/445 , A61K31/495 , A61K31/496
摘要： The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.
摘要翻译： 本发明涉及11-β-羟基类固醇脱氢酶1型酶抑制剂的用途。 本发明还涉及11-β-羟基类固醇脱氢酶1型酶抑制剂用于治疗或预防性治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其它疾病的用途，以及 过度糖皮质激素作用介导的病症。
-
公开(公告)号：US20060148871A1
公开(公告)日：2006-07-06
申请号：US11325956
申请日：2006-01-05
申请人： Jeffrey Rohde , Liping Pan , Marina Pliushchev , James Link
发明人： Jeffrey Rohde , Liping Pan , Marina Pliushchev , James Link
摘要： The present invention is directed to the method of increasing the metabolic stability of adamantane containing compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 (11-beta-HSD-1) enzyme. The stability is achieved by substitutions of the adamantane ring.
摘要翻译： 本发明涉及增加含有金刚烷的化合物（其为11-β-羟基类固醇脱氢酶1型（11-β-HSD-1））的抑制剂的代谢稳定性的方法。 稳定性通过金刚烷环的取代来实现。
-
7.发明申请公开(公告)号：US20050261302A1
公开(公告)日：2005-11-24
申请号：US11116849
申请日：2005-04-28
申请人： Ethan Hoff , James Link , Marina Pliushchev , Jeffrey Rohde , Martin Winn
发明人： Ethan Hoff , James Link , Marina Pliushchev , Jeffrey Rohde , Martin Winn
IPC分类号： A61K31/16 , A61K31/40 , A61K31/445 , A61K31/495
CPC分类号： A61K31/16 , A61K31/40 , A61K31/445 , A61K31/495
摘要： The present invention relates to the use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment or prophylactically treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions mediated by excessive glucocorticoid action.
-
公开(公告)号：US20140171429A1
公开(公告)日：2014-06-19
申请号：US13979388
申请日：2012-01-20
申请人： Anil Vasudevan , Thomas Dale Penning , Huanming Chen , Bo Liang , Shaohui Wang , Zhongqiang Zhao , Dikun Chai , Leifu Yang , Yingxiang Gao , Marina Pliushchev
发明人： Anil Vasudevan , Thomas Dale Penning , Huanming Chen , Bo Liang , Shaohui Wang , Zhongqiang Zhao , Dikun Chai , Leifu Yang , Yingxiang Gao , Marina Pliushchev
IPC分类号： C07D471/04
CPC分类号： C07D471/04 , C07D401/12
摘要： The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, Formula (1) wherein R1, R2, R3, X, Y, Z, A, B, G1, m, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.
摘要翻译： 本发明涉及式（1）化合物或其药学上可接受的盐，式（1）其中R 1，R 2，R 3，X，Y，Z，A，B，G 1，m和n在说明书中定义。 本发明还涉及含有可用于抑制ALK等激酶的化合物的组合物和治疗诸如癌症的疾病的方法。
-
公开(公告)号：US09212192B2
公开(公告)日：2015-12-15
申请号：US13979387
申请日：2012-01-20
申请人： Anil Vasudevan , Thomas Dale Penning , Huanming Chen , Bo Liang , Shaohui Wang , Fengchun Wu , Yan Shen , Cuihua Liu , Zhenguang Zou , Marina Pliushchev
发明人： Anil Vasudevan , Thomas Dale Penning , Huanming Chen , Bo Liang , Shaohui Wang , Fengchun Wu , Yan Shen , Cuihua Liu , Zhenguang Zou , Marina Pliushchev
IPC分类号： C07D487/04 , A61K31/4353 , A61P35/00 , C07D519/00 , C07D471/04
CPC分类号： C07D519/00 , A61K31/4353 , C07D471/04 , C07D487/04
摘要： Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X1˜X5, R1˜R3, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.
摘要翻译： 提供式（I）化合物或药学上可接受的盐，其中X 1，X 5，R 1〜R 3，A，B，Z和n在说明书中定义。 并提供含有所述化合物的组合物，以及用于激酶例如ALK的用途及其用于治疗癌症的用途。
-
公开(公告)号：US20140155389A1
公开(公告)日：2014-06-05
申请号：US13979389
申请日：2012-01-20
申请人： Anil Vasudevan , Thomas Dale Penning , Huanming Chen , Bo Liang , Shaohui Wang , Zhongqiang Zhao , Dikun Chai , Leifu Yang , Yingxiang Gao , Marina Pliushchev
发明人： Anil Vasudevan , Thomas Dale Penning , Huanming Chen , Bo Liang , Shaohui Wang , Zhongqiang Zhao , Dikun Chai , Leifu Yang , Yingxiang Gao , Marina Pliushchev
IPC分类号： C07D471/04 , C07D401/12
CPC分类号： C07D471/04 , C07D401/12
摘要： The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.
摘要翻译： 本发明涉及式（1）化合物或其药学上可接受的盐，其中R1，X，Y，Z，A，B，G1和n在说明书中定义。 本发明还涉及含有可用于抑制ALK等激酶的化合物的组合物和治疗诸如癌症的疾病的方法。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.026 秒)
